Sanofi, Regeneron pad Dupixent’s case in adolescent eczema ahead of key asthma decision

dupixent
Sanofi and Regeneron hopes the positive data could help it win approvals in adolescent eczema. (Sanofi)

Still waiting for a key FDA decision in asthma, Sanofi and Regeneron’s Dupixent has cut in with positive clinical results in adolescents with atopic dermatitis, an indication in which it’s currently approved for adults.

When used alone, the type 2 inflammation drug demonstrated significant improvement in teenagers aged 12 to 17 with atopic dermatitis, according to phase 3 results detailed at the European Academy of Dermatology and Venereology Congress in Paris.

About 41.5% of patients receiving Dupixent every two weeks and 38% of those on an every-four-week schedule saw skin improvement of 75% or greater, compared to 8% for placebo. Using a different criterion to assess the results, about every 1 in 4 patients who got weight-based dosing every two weeks achieved clear or almost-clear skin, versus 2% for those on a dummy drug. Plus, some additional secondary endpoints were also met.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

For these teenagers with moderate-to-severe eczema, topical therapies are either unable to control the disease or are simply not applicable. The new results show Dupixent can “not only help clear the skin and reduce itching, but also improve certain aspects of quality of life in adolescents who may be dealing with these unbearable symptoms,” said Amy Paller, M.D., of Northwestern University and principal investigator of the trial.

The partners now hope the readouts could serve as the basis of regulatory submissions in this age group, and it is also looking to file for approval in children as young as six in the second half of 2019.

RELATED: AbbVie eczema candidate has analysts whittling down super-rich forecasts for Sanofi and Regeneron's Dupixent

But perhaps more important for them is an FDA decision expected next month on asthma, an indication analysts at Bernstein predicted could add $2.5 billion in peak sales for the drug.

In a previous phase 3 on more than 1,900 patients, including adults and adolescents, the drug, when compared to standard therapies, reduced severe asthma attacks by 46% in all patients. What’s more, it also improved lung function. Even though the benefit was greater among patients with high levels of eosinophilic cells, management has said they expect an approval regardless of eosinophils level.

The Dupixent launch has been going well for the companies, as sales reached €176 million ($206 million) during the second quarter. Total prescriptions in the U.S. also grew 27% sequentially, and patient initiations were growing on a weekly speed of more than 800 patients, said Genzyme chief Bill Sibold on the second-quarter earnings call.

However, competition is coming for both those indications. AbbVie recently posted full positive atopic dermatitis results for its JAK1 inhibitor upadacitinib, while AstraZeneca and Amgen’s tezepelumab was granted an FDA breakthrough designation in severe asthma without an eosinophilic phenotype.

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.